PROM1 and ovarian carcinoma: We thus developed a poly(methylmethacrylate) (PMMA)-polyvinylpyrrolidone (PVP) NP that conjugated with CD133 and levamisole (LEVA) to fight against the ovarian cancer cell line by using the bioconjugation method.